Journal
GLAND SURGERY
Volume 10, Issue 3, Pages 1173-1181Publisher
AME PUBLISHING COMPANY
DOI: 10.21037/gs-2019-ursoc-08
Keywords
Ovarian cancer; optimal cytoreduction; prediction
Categories
Funding
- Pusan National University Yangsan Hospital
Ask authors/readers for more resources
The main management of advanced ovarian cancer is maximal cytoreductive surgery followed by chemotherapy. Alternative treatments include neoadjuvant chemotherapy and interval debulking surgery for patients who are not suitable for maximal cytoreductive surgery. Predicting optimal debulking before treatment is crucial for the successful management of ovarian cancer, with various biomarkers and imaging studies being used for this purpose.
The mainstay management of advanced ovarian cancer is maximal cytoreductive surgery followed by chemotherapy. Neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) are alternative treatments for patients with comorbidity, poor performance status, and predicted for suboptimal debulking surgery. It is the invariable principle in any situation that no residual disease after the completion of surgery is useful for patients with ovarian cancer. Therefore, the prediction of optimal debulking before the treatment of ovarian cancer is of utmost importance. Many studies have reported on the use of serum biomarkers, such as cancer antigen 125 (CA125) or human epididymis 4 (HE4), and imaging studies, such as computed tomography (CT), diffusion-weighted magnetic resonance imaging (DW-MRI), and positron emission tomography (PET)/CT, to identify adequate surgical candidates for primary debulking surgery (PDS). Laparoscopy has also been studied as a reliable tool for the prediction of optimal debulking. Here, we summarize a review of the related literature.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available